Key result
SGLT2 inhibitors show ~30-point lower 12-month persistence in CAD compared with aspirin.
Why the study?
The 2024 ESC chronic coronary syndromes guidelines assign SGLT2 inhibitors a Class I, Level A recommendation for patients with type 2 diabetes, yet ongoing SGLT2i use in CAD had not been benchmarked against other guideline-directed medical therapies within the same multinational cohort.
Do SGLT2 inhibitors have comparable estimated 12-month ongoing use relative to other guideline-directed medical therapies in patients with coronary artery disease across European centres?
Cross-Sectional (n=30)
Yes
Do SGLT2 inhibitors have comparable estimated 12-month ongoing use relative to other guideline-directed medical therapies in patients with coronary artery disease across European centres?
Despite Class I ESC recommendations, SGLT2 inhibitors have the lowest estimated 12-month ongoing use (55.2%) among six guideline-directed CAD therapies in Europe, driven primarily by lower initial uptake rather than faster attrition.
Answers are grounded in this paper and cite their sources.
Low 12-month SGLT2i use estimates in CAD urge closer persistence tracking; leaves open whether actual patient data confirm these gaps.
Background The 2024 ESC chronic coronary syndromes guidelines assign SGLT2 inhibitors (SGLT2i) a Class I, Level A recommendation for patients with type 2 diabetes, yet SGLT2i ongoing use in coronary artery disease (CAD) has not been benchmarked against other guideline-directed medical therapies (GDMT) within the same multinational cohort. Purpose To quantify SGLT2i ongoing-use trajectories in CAD and rank SGLT2i against other GDMT at standardised timepoints across European centres. Methods Cross-sectional web-based survey of cardiologists across 15 European countries (CAD module: n=30). Respondents estimated the proportion of eligible patients remaining on each of eight drug classes at 3, 6, and 12 months post-index event ("estimated ongoing use"), capturing both initiation and persistence. Six GDMT classes were compared: aspirin, P2Y12 inhibitors, statins, ACEi/ARB, beta-blockers, and SGLT2i. Within-class change from 3 to 12 months was tested with paired comparisons; between-class differences at 12 months with non-parametric tests. From a separate heart failure module (n=32), SGLT2i initiation intent was extracted to distinguish prescribing gaps from persistence gaps. Results At 12 months, SGLT2i had the lowest estimated ongoing use among all six GDMT classes (55.2%; 95% CI 46.1–64.3), followed by beta-blockers (55.9%), ACEi/ARB (67.4%), P2Y12 inhibitors (69.2%), statins (75.3%), and aspirin (85.5%). SGLT2i was already among the lowest at 3 months (65.5%, comparable to beta-blockers at 65.8%) and declined by 7.5 percentage points over the following nine months. This decline parallels the attrition observed for established therapies including aspirin (−9.7 pp), suggesting that the low 12-month level is driven by a lower starting point rather than faster attrition. At 12 months, SGLT2i was 30.3 percentage points below aspirin (p<0.0001) and 20.1 points below statins. 40% of centres reported <50% ongoing use at 12 months. Country-level means ranged from 32% to 74%, reflecting substantial cross-national variability. In the heart failure module, 91% of respondents reported initiating SGLT2i always or usually when indicated, suggesting that persistence gaps, not prescribing intent, drive the shortfall. Conclusion Among 6 guideline-directed CAD therapies surveyed across 15 European countries, SGLT2 inhibitors show the lowest estimated 12-month ongoing use despite Class I ESC recommendations. The rate of adherence attrition is comparable to established therapies; so the problem is not the slope, it is the starting line. A 30-point gap versus aspirin and a 12-month floor of 55.2% suggest that prescribing inertia and suboptimal initiation at discharge, rather than differential patient dropout, are the primary drivers of value loss. These findings support prioritising discharge-level interventions (systematic initiation, titration protocols, and structured follow-up plans) over strategies focused solely on long-term persistence.
No takes yet. Share an insight, caveat, or question.
Tjon et al. (2026) conducted a cross-sectional in Coronary artery disease (n=30). SGLT2 inhibitors vs. Other guideline-directed medical therapies (aspirin, statins, P2Y12 inhibitors, ACEi/ARB, beta-blockers) was evaluated on Estimated ongoing medication use at 12 months post-index event (-30.3 percentage points vs aspirin, 95% CI 46.1-64.3, p=<0.0001). SGLT2 inhibitors had the lowest estimated 12-month ongoing use among six CAD therapies, 30.3 percentage points below aspirin.
Synapse has enriched 10 related papers. Consider them for comparative context: